Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aesthetic Tissue Welding (ATW) was a specialized subsidiary of CSMG Technologies, Inc., established in 2008 to focus on the application of laser-mediated tissue welding in cosmetic and plastic surgery. The company utilized a proprietary technology developed by Dr. Yasmin Wadia, which employs a laser-biologic combination—specifically a human serum albumin-based solder—to fuse tissues instantly without sutures or staples. This "point, aim, and fuse" method was designed to reduce surgical time, minimize scarring, and improve healing for elective procedures such as skin grafts and incisions. ATW operated under CSMG's Live Tissue Connect division alongside other procedure-specific units, but the parent company has since become inactive, with the core technology continuing under Laser Tissue Welding, Inc.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aesthetic Tissue Welding.